

Phone: 855-856-0536 Fax: 877-342-4596

Pulmonary Arterial Hypertension Enrollment Form

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy – tear here.

This form is not a valid prescription in Arizona

Please complete the follow	ATION	PRESCRIBER IN	FORMATION		
	Please complete the following or send patient demographic sheet				
Patient Name		DEA			
Address		NPI			
Address 2		Group/Hospital			
City, State, ZIP		Address			
•		City, State, ZIP			
	Alternate Phone				
	est Four of SS# Gender		Fax		
	nglish Spanish Other	Contact Person	Phone		
INSURANCE INFO	RMATION (Must fax a copy of patient's insurance car	rd including both sides)			
Prior Authorization Reference	e number				
MEDICAL INFORM	IATION (Section must be completed to p	rocess prescription	(Attach separate sheet if neede	ed)	
Diagnosis — Please include diagnosis with ICD-10 code		Additional Information	Therapy: New Reauth	norization	Restart
Primary Pulmonary arterial hypertension (PAH)—127.0		Weight	kg/lbs Height		cm/in
☐ Idiopathic ☐ Familial		Allergies			
Secondary Pulmonary arterial hypertension (PAH)—127.21		Lab Data			
Connective Tissue Disorder HIV CTEPH Associated		Prior Therapies			
Other specified pulmonary heart diseases—I27.89					
Other Diagnosis: ICD-10 Code		Concomitant Medications			
Description		Oxygen Therapy			
Date of Diagnosis		Oxygen Therapy			
NYHA Functional Classification: I I II III III IV					
Mean PAP PAOP		Additional Comments			
ŕ	ivity				
Start Date Review Date					
PRESCRIPTION INFORMATION Medication Dose/Strength		Die	rections	Ouentitu	Refills
	Dose/Strength 5 mg Tablet	Dir	ections	Quantity	neillis
Ambrisentan Patient enrollment required in	☐ 10 mg Tablet			1	
Ambrisentan REMS program. Please call 888-417-3172.					
Ambrisentan REMS program.	62.5 mg Tablet				
Ambrisentan REMS program. Please call 888-417-3172.	62.5 mg Tablet 125 mg Tablet				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612.	125 mg Tablet				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program.	l				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612.	125 mg Tablet				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612.	125 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil	125 mg Tablet 20 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 20 mg Tablet 125 mg Tablet				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil Tracleer® Patient enrollment required in	125 mg Tablet 20 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 32 mg Tablet for Oral Suspension				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil Tracleer®	125 mg Tablet 20 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 20 mg Tablet 125 mg Tablet				
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil Tracleer® Patient enrollment required in Bosentan REMS program. Please call 866-359-2612.	125 mg Tablet 20 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 32 mg Tablet for Oral Suspension	nd initiate the insurance prior authorizatio alues and other patient data. In the event	n process for my patient(s), and to sign any necet that this pharmacy determines that it is unable to		
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil Tracleer® Patient enrollment required in Bosentan REMS program. Please call 866-359-2612.	125 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 32 mg Tablet 32 mg Tablet 5 mg and 125 mg tablets.	nd initiate the insurance prior authorization alues and other patient data. In the event rmacy of the patient's choice or in the pat	n process for my patient(s), and to sign any necet that this pharmacy determines that it is unable to	o fulfill this prescription	
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil Tracleer® Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. **Prescriber Authorization: I authorize this authorized agent, including the receipt of authorize this pharmacy to forward this in	125 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 32 mg Tablet 32 mg Tablet 5 mg and 125 mg tablets.	nd initiate the insurance prior authorization alues and other patient data. In the event rmacy of the patient's choice or in the pat	n process for my patient(s), and to sign any neces that this pharmacy determines that it is unable to ient's insurer's provider network.	o fulfill this prescription	
Ambrisentan REMS program. Please call 888-417-3172. Bosentan Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. Sildenafil Tadalafil Tracleer® Patient enrollment required in Bosentan REMS program. Please call 866-359-2612. *Prescriber Authorization: I authorize this authorized agent, including the receipt of authorize this pharmacy to forward this in Ship to: Patient	125 mg Tablet 20 mg Tablet 10 mg/12.5 mL IV Solution 10 mg/mL Powder for Oral Suspension 20 mg Tablet 32 mg Tablet for Oral Suspension See Bosentan for 62.5 mg and 125 mg tablets.	nd initiate the insurance prior authorization alues and other patient data. In the event rmacy of the patient's choice or in the pat	n process for my patient(s), and to sign any neces that this pharmacy determines that it is unable to lent's insurer's provider network. Therapy Start Date	of ulfill this prescription	

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona.